EI
NTLA icon

Ellevest Inc’s Intellia Therapeutics NTLA Stock Holding History

Ellevest Inc’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-279
Closed -$10.4K – 1194
2023
Q1 		$10.4K Buy
+279
New +$10.9K ﹤0.01% 1017
2022
Q4 		– Sell
-21
Closed -$999 – 1927
2022
Q3 		$1K Buy
21
+12
+133% +$744 ﹤0.01% 1489
2022
Q2 		$0 Sell
9
-25
-74% -$1.27K ﹤0.01% 1586
2022
Q1 		$2K Sell
34
-3
-8% -$254 ﹤0.01% 1209
2021
Q4 		$4K Sell
37
-32
-46% -$4.01K ﹤0.01% 1061
2021
Q3 		$9K Buy
69
+15
+28% +$2.27K ﹤0.01% 841
2021
Q2 		$9K Sell
54
-37
-41% -$2.88K ﹤0.01% 791
2021
Q1 		$7K Buy
91
+46
+102% +$3.09K ﹤0.01% 844
2020
Q4 		$2K Buy
45
+19
+73% +$690 ﹤0.01% 984
2020
Q3 		$1K Buy
26
+8
+44% +$167 ﹤0.01% 1042
2020
Q2 		$0 Sell
18
-3
-14% -$51 ﹤0.01% 1268
2020
Q1 		$0 Sell
21
-37
-64% -$498 ﹤0.01% 1232
2019
Q4 		$1K Buy
+58
New +$807 ﹤0.01% 827

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ellevest Inc's NTLA Position: Q2 2023 in Review

Ellevest Inc sold out of Intellia Therapeutics (NTLA) in Q2 2023, closing a stake of 279 shares — an estimated $10.4K sold.

Ellevest Inc first reported a position in NTLA in Q4 2019 and held it in 13 quarters. The position peaked at $10.4K in Q1 2023. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2023.

  • Ellevest Inc reported no remaining Intellia Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 279 Intellia Therapeutics shares in Q2 2023, an estimated $10.4K.
  • Ellevest Inc first reported a position in Intellia Therapeutics in Q4 2019 and held it in 13 quarters.
  • Ellevest Inc's Intellia Therapeutics position peaked at $10.4K in Q1 2023.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.